CHARLOTTE, N.C., Feb. 23, 2023 /PRNewswire/ -- MedSource Labs (Chanhassen, MN) has been awarded a group purchasing agreement for Peripheral Intravenous Catheters (PIVC) Solutions with Premier's AscenDrive™ program, which is designed to drive the highest-level commitment and savings for members through aggregated purchasing of high-quality products and services.
The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the ClearSafe® and TrueSafe® families of products. The AscenDrive™ program brings together Premier's most committed members to coordinate purchasing decisions and maintain standardization across their facilities. By providing additional value to Premier contracted suppliers through volume and commitment, the program is expected to achieve best-in-market pricing.
"We are thrilled to have been awarded this agreement, which can allow Premier members to secure enhanced savings and exclusive benefits on high-quality peripheral IV catheters," said Todd Fagley, Founder of MedSource Labs. "We know through this collaboration MedSource will help to shape the future of safety catheters in the U.S. and beyond."
PERIPHERAL IV CATHETER MARKET
At an estimated annual spend of over $5 billion in the US alone, Peripheral Intravenous Catheter insertion (PIVC) is a routine hospital procedure used during the administration of intravenous drugs, blood products and parenteral medication. 98% of all acute care admissions will receive at least one peripheral IV catheter on admission.
Premier, Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,400 U.S. hospitals and health systems and approximately 250,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.
ABOUT MEDSOURCE LABS
Celebrating 20 years as a trusted provider of quality medical products, MedSource Labs specializes in customized, Class II product development, manufacturing and commercialization using our comprehensive EMERGE process—transforming good ideas into market-ready medical devices.
Last Trade: | US$21.16 |
Daily Change: | 0.07 0.33 |
Daily Volume: | 2,291,754 |
Market Cap: | US$2.030B |
December 03, 2024 November 05, 2024 August 19, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load